Panic Disorders
Conditions
Keywords
Panic Disorders
Brief summary
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
Interventions
DRUGParoxetine
DRUGVENLAFAXINE
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1. * Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit. * Provide a written informed consent
Exclusion criteria
* Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine * Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine. * Psychopharmacologic drugs within 14 days of study day 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine. | — |
Countries
Brazil
Outcome results
None listed